NHS England has announced a pause on new dispensing of cross-sex hormones for 16 and 17-year-olds questioning their gender identity, in the wake of a thorough examination that determined previous research into the drugs’ safety and effectiveness was insufficient. The decision, which takes effect immediately, comes after an independent evidence review ordered by the health service concluded there was inadequate quality evidence to determine whether the hormones help or damage young people. Teenagers already receiving the treatment will keep taking their medication, though clinicians will be asked to review their cases. NHS England said a small number of young people would be impacted by the pause and will be provided with other treatment options at three gender clinics operated by the NHS for children operating across England.
The Choice and Its Scope
The pause represents a notable transition in NHS England’s handling of gender-affirming medical care for adolescents. Cross-sex hormones, which help individuals develop physical traits connected to their chosen gender, can produce irreversible changes including a more masculine voice, chest development, or other lasting changes. The choice to pause new prescriptions stems from the NHS’s evaluation that available evidence cannot conclusively determine whether these treatments help or harm young people experiencing gender distress. Professor James Palmer, National Medical Director for Specialised Services at NHS England, stressed that the review had been “extremely thorough and intricate,” finally concluding that available evidence does not support continued use of masculinising or feminising hormones for under-18s.
NHS England has started a 90-day public consultation starting Monday to collect additional feedback on the updated policy and review results. The health service hopes this consultation period will identify any evidence that could have been missed during the original review. Existing guidance already prohibited prescriptions for under-16s requesting gender-related treatment, so the new suspension essentially broadens restrictions to include 16 and 17-year-olds. The NHS emphasized its commitment to providing full support, stating that young people who cannot receive hormone therapy will be provided with alternative care options through its three dedicated gender clinics for children across England.
- Pause covers new prescriptions for 16 and 17-year-olds only
- Young people presently taking hormones will proceed with existing treatment
- Clinicians will examine existing cases for ongoing suitability
- Alternative care available at three NHS gender clinics nationally
Evidence Assessment Results
The decision to pause hormone prescriptions stems directly from a comprehensive evidence review ordered by NHS England, which examined the scientific basis for cross-sex hormone treatment in young people. The review, consisting of ten separate evaluations of different aspects of testosterone and oestrogen use, uncovered notable deficiencies in the evidence supporting current medical practice. NHS England determined that the available evidence was insufficient to determine whether these therapies help or harm adolescents experiencing gender dysphoria, making it impossible to support the continuation of new prescriptions with confidence in their safety and effectiveness.
This conclusion aligns with concerns raised in Dr Hilary Cass’s major April 2024 review on gender care for children, which noted “notably insufficient” data surrounding clinical treatments in this field. The Cass report encouraged NHS England to undertake its own comprehensive evaluation of the research foundation. The resulting assessment addressed multiple outcomes for younger patients, including life quality, mental health, and overall wellbeing. Rather than delaying for further evidence to develop, NHS England opted to implement a cautious strategy, suspending new prescriptions while continuing to evaluate feedback from patient advocates and healthcare professionals.
What the Data Revealed
The ten independent evidence assessments analyzed the effects of hormone hormones covering health and psychological outcomes for adolescents with a different gender from their biological sex. Researchers assessed published studies on the way such therapies impacted life quality, mental health status, and gender-related distress in young people. The review was deliberately comprehensive, aiming to examine all available evidence in assessing whether adequate evidence was available to justify ongoing prescription for under-18s.
The overall conclusion was stark: the available evidence did not satisfy the standard necessary to reliably endorse hormone treatment for this demographic. Professor Palmer stated that the review “established that the available evidence does not support the continued use of hormone treatments” to treat young people under 18 with gender-related conditions. This finding indicated NHS England could not definitively say whether the interventions were beneficial or detrimental, requiring a suspension pending further clarification and clinical guidance.
- Ten independent reviews examined multiple facets of endocrine treatment
- Research assessed wellbeing and emotional health effects
- Available evidence deemed insufficient to support continued prescriptions
- Insufficient data to show if therapies harm or help adolescents
Public Response and Legal Battles
The NHS decision to pause hormone prescriptions has prompted swift and polarised responses from across the healthcare and advocacy sectors. Trans advocacy groups have expressed strong opposition to the policy shift, with some organisations indicating their plans to take legal proceedings against NHS England. These groups contend that the pause limits availability to transformative treatment for young people with gender dysphoria, and contend that the evidence assessment does not support such a limiting stance. The consultation phase starting Monday will be crucial in establishing whether NHS England’s stance shifts or strengthens based on stakeholder input.
Healthcare practitioners working in gender identity programs have also shared their views on the decision, with views spanning from cautious support to significant concern. Some clinicians welcome the evidence evaluation as a essential measure to verify treatments are sufficiently evidence-based, while others express concern that the pause may negatively affect vulnerable young people who have already begun hormone therapy or are seeking to obtain care. The 90-day review period serves as an opportunity for these different stakeholders to put forward their perspectives, possibly affecting whether the temporary pause becomes permanent policy or is modified based on new evidence or professional consensus.
| Group | Position |
|---|---|
| Trans Advocacy Organisations | Opposing the pause; considering legal action against NHS England |
| Some Healthcare Professionals | Supporting cautious approach; welcoming evidence-based review |
| Other Clinicians | Concerned about harm to young people already in treatment |
| NHS England Leadership | Defending precautionary approach; seeking further consultation |
Advocacy Organization’s Response
Trans advocacy groups have criticised the NHS pause as unfairly restrictive and potentially harmful to at-risk adolescents. These groups argue that the choice to stop fresh prescriptions conflicts with the experiences of transgender adolescents who describe enhanced mental wellbeing and standard of living following hormone treatment. They argue that the review’s findings of “weak evidence” does not justify such a restrictive policy, and that the pause practically withholds care to people with the greatest need while awaiting perfect scientific certainty that may never materialise.
Court battles appear likely, with civil rights organisations indicating they will pursue legal proceedings to challenge or alter the medication freeze. These bodies contend that the decision infringes upon the rights of youth to obtain proper treatment and might represent bias against gender identity. They emphasise that personalised medical assessments ought to decide access to treatment as opposed to blanket restrictions, and that the consultation process needs to thoroughly review accounts from trans communities directly about personal experiences with hormone therapy.
Private Sector and Global Framework
While NHS England adopts its measured approach, the private healthcare sector in the UK keeps providing hormone treatments to teenagers outside the state healthcare provision. This establishes a two-tier system where affluent households may access treatments that the NHS has paused, generating questions about equal access and fairness. The divergence between NHS policy and private provision draws attention to fundamental issues about how research-backed standards should apply across various healthcare environments, and whether teenagers’ ability to access to gender-affirming medical care should depend on their household income rather than medical necessity.
Internationally, healthcare systems have implemented varying approaches to hormone treatment for young people questioning their gender. Some European countries, such as Sweden and Finland, have likewise restricted restrictions on gender-affirming hormones for minors in the past several years, pointing to a lack of evidence. Conversely, other nations uphold more liberal prescribing policies, with some medical organisations contending that denying treatment causes greater psychological harm. These divergent international responses underscore the real scientific debate surrounding the long-term effects and benefits of these interventions, and suggest that no consensus yet exists among global medical authorities on the suitable course of treatment for young people experiencing gender dysphoria.
- Private clinics in the UK persist in providing hormone treatments to minors despite NHS pause
- Sweden and Finland have likewise limited hormonal medications for minors in the past few years
- International health bodies stay split on proper treatment guidelines for young people
The Next Steps
NHS England has initiated a structured process to establish its future direction on hormonal therapy for teenagers questioning their gender. A three-month public engagement commenced on Monday will seek input from campaign organizations, medical practitioners, and the wider public on the review outcomes and updated recommendations. The health service has emphasised that this consultation period is essential for finding any evidence that may have been overlooked during the first review stage. The outcomes will directly shape whether the current pause on novel treatments becomes long-term policy or whether treatment restarts under adjusted guidelines.
During the review timeframe, NHS England will maintain oversight of young people presently on hormone treatment, with clinicians conducting individualised reviews of each patient’s care plan. The three established NHS gender clinics for children will expand their provision of alternative forms of care for those without access to hormones, including psychological support and counselling services. Following the 90-day period, NHS England will analyse all feedback received and make a final decision regarding long-term policy. This decision will have substantial impact for many young people across England accessing gender-affirming care.
The 90 Day Advisory Process
The consultation constitutes a formal opportunity for stakeholders to challenge or support NHS England’s initial conclusions. Advocacy groups, medical professionals, and members of the public can submit evidence and perspectives on whether the review correctly represents current scientific understanding. Trans advocacy organisations have already indicated they may take legal action, suggesting the consultation will be contentious. NHS England has indicated it will carefully review all responses, particularly seeking to identify any robust evidence that the initial review may have overlooked or given insufficient weight to in its analysis.
The 90-day window is designed to reconcile the requirement for comprehensive deliberation with the urgency of delivering clear guidance to young people and healthcare providers presently unclear about access to treatments. NHS England will compile and assess all feedback received before issuing its final decision on new guidance. This longer timeframe permits healthcare professionals to express practical experience, academic bodies to provide further data, and youth themselves to describe how the revised policies affect their wellbeing and quality of life.
